Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

AIMS: Concern about hypotension often leads to withholding of beneficial therapy in patients with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and safety of dapagliflozin, which lowers systolic blood pressure (SBP),according to baseline SBP in Dapagliflozin and Prev...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur Heart J
Hlavní autoři: Serenelli, Matteo, Böhm, Michael, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Solomon, Scott D, DeMets, David L, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna Maria, Anand, Inder S, Chiang, Chern-En, Chopra, Vijay K, de Boer, Rudolf A, Diez, Mirta, Dukát, Andrej, Ge, Junbo, Howlett, Jonathan G, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E A, Verma, Subodh, Docherty, Kieran F, Jhund, Pardeep S, McMurray, John J V
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Clinical Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7550197/
https://ncbi.nlm.nih.gov/pubmed/32820334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa496
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky